Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784592 | 0.90 | WDR5 (0.36) | WDR5SMOKLKB1PDE10ABTK | |
| SCHEMBL785366 | 0.90 | WDR5 (0.38) | WDR5SMOKLKB1PDE10ABTK | |
| SCHEMBL784457 | 0.89 | WDR5 (0.36) | WDR5SMOKLKB1PDE10ABTK | |
| SCHEMBL785498 | 0.88 | PDE4A (0.37) | WDR5SMOKLKB1PDE10APOLB | |
| SCHEMBL785737 | 0.88 | MEN1 (0.39) | WDR5POLBLMNAALDH1A1 | |
| SCHEMBL785506 | 0.85 | TAF1 (0.38) | WDR5SMOKLKB1ALDH1A1ACKR3 | |
| SCHEMBL785107 | 0.84 | WDR5 (0.37) | WDR5SMOPDE10APOLBALDH1A1 | |
| SCHEMBL785488 | 0.84 | GBA1 (0.38) | WDR5SMOKLKB1ALDH1A1HCRTR1 | |
| SCHEMBL784800 | 0.84 | WDR5 (0.40) | WDR5SMOKLKB1ALDH1A1ACKR3 | |
| SCHEMBL785902 | 0.83 | CTSS (0.36) | WDR5SMOKLKB1PDE10APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | WDR5 2611/4885SMO 4034/4885KLKB1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.